Topoisomerase I Inhibiting Compounds for Breast Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current Topoisomerase I inhibitors, such as camptothecin derivatives, have unstable chemical structures, leading to rapid reversibility of DNA cleavage complexes and cellular resistance, necessitating the development of stable non-camptothecin compounds that can effectively inhibit Topoisomerase I to induce cancer cell death.
Innovation Solution
Development of compounds with the general formula I, featuring specific aromatic heterocyclic groups and hydrophilic functional moieties, which stabilize the drug-DNA-Topoisomerase I ternary complex, thereby enhancing their anticancer activity and stability at physiological pH.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If camptothecin derivatives are used as Topoisomerase I inhibitors, then they can stabilize the drug-DNA-Topoisomerase I ternary complex and induce cancer cell death, but they possess inherently unstable chemical structure due to opening of the lactone ring, leading to rapid reversibility of cleavage complexes and cellular resistance
Solution Approach 1:
The patent changes the chemical structure parameters by replacing the lactone ring structure of camptothecin with alternative cyclic structures (such as cyclopenta[c]pyridine, indole, or carbazole rings) that maintain the ability to stabilize the drug-DNA-Topoisomerase I ternary complex while avoiding the chemical instability and rapid reversibility associated with the lactone ring opening and closing equilibrium
Solution Approach 2:
The patent creates composite molecular structures by combining specific heterocyclic core structures (cyclopenta[c]pyridine, indole, carbazole) with aromatic heterocyclic groups and hydrophilic functional moieties, forming new hybrid compounds that achieve both stable ternary complex formation and resistance to cellular efflux pumps
2Reliability
If camptothecin derivatives are used as Topoisomerase I inhibitors, then they can inhibit Top I function and cause death of dividing cells, but they suffer from rapid cellular efflux via membrane pumps and develop cellular resistance
Solution Approach 1:
The patent modifies molecular parameters by introducing specific hydrophilic functional groups (such as carboxylic acid, hydroxyl, or amino groups) and aromatic heterocyclic substituents that alter the compounds' recognition by efflux pumps, thereby reducing cellular efflux and preventing the development of resistance while maintaining Topoisomerase I inhibition activity
3Stability of the object's composition
If stable non-camptothecin compounds are developed to inhibit Topoisomerase I, then they can avoid rapid reversibility of cleavage complexes, but they require specific structural features (aromatic heterocyclic groups and hydrophilic functional moieties) that increase molecular complexity
Solution Approach 1:
The patent segments the molecular structure into distinct functional modules: a core heterocyclic structure (cyclopenta[c]pyridine, indole, or carbazole), aromatic heterocyclic groups (pyridine, pyrimidine, triazine rings), and hydrophilic functional moieties. This modular segmentation allows systematic optimization of stability and activity while managing molecular complexity through defined structural units
Solution Approach 2:
The patent achieves universality by designing a platform of compounds with a common core structure that can accommodate various aromatic heterocyclic groups and hydrophilic functional moieties, allowing a single structural framework to provide multiple benefits including stable ternary complex formation, reduced efflux, and maintained anticancer activity across a series of derivatives
Data Source
AI summary
The invention described herein relates to the compounds of Formula I for treating diseases and disorders for which inhibition or modulation of the topoisomerase I enzyme produces a physiologically beneficial response, in particular for the treatment of breast cancer. Also provided is the process of preparing compounds of Formula I.